Morpheus Complete MD1-123/124

SHARE

Mail Icon Google+ Facebook Twitter

Product Image

Achieve more hits and save money with this exclusive offer on new Morpheus® Complete screen set.


Morpheus I, II and III were designed by Dr Fabrice Gorrec of the MRC-LMB, Cambridge, UK and optimised against a range of samples to avoid bias toward specific protein families. New Morpheus Complete bundles all three screens together and until Morpheus formulations31st December 2018 it's available at a great introductory low price, providing a saving of 40% compared to buying the kits separately. So now you can achieve more crystal hits for better value than ever before.

Order now to receive a free Morpheus® formulations chart (above): An A2 poster that will make identifying and optimising your Morpheus hit conditions simple!

You can learn about the methodolgy behind the screen development in this webinar describing the four-corner method for optimizing Morpheus® hit conditions.


Morpheus Complete contains:


Morpheus® screen
This ever popular screen incorporates a range of low molecular weight compounds that were identified as frequently occurring ordered ligands in more than 33,000 structures from the PDB (PDB data from 2009). This unique screen aims to access novel chemical space left unexplored in conventional screens, primarily by integrating PDB-derived ligands in 8 additive mixes. Each mix contains a number of additives of the same chemical class.
Reference: Gorrec, F. The MORPHEUS protein crystallization screen. Journal Applied Crystallography 42: 1035-42 (2009).

Morpheus® II screen
A follow-up to the popular Morpheus® screen, Morpheus® II has been developed using the same approach (including low molecular weight compounds identifed as protein ligands in the PDB in 2015). However, in Morpheus® II, reagents not found in Morpheus or other initial screens have been integrated to access new areas of crystallization space and provide useful hits when other screens have failed.
The 96 conditions include NDSBs, polyamines, amino acids and monosaccharides to increase protein solubility and stability. As with Morpheus®, these are combined in several mixes for efficient screening. Glycerol-like polyols are used for cryoprotection and some heavy atoms are included to aid experimental phasing. Finally, more innovative buffer systems are used.
References: Gorrec, F. The Morpheus II protein crystallization screen. Acta Crystallographica section F Structural Biology Communications 71: 831-837 (2015).
The Morpheus® III screen
Morpheus III contains a range of small drug-like molecules (Average RMM = 248). The compounds include antibiotics, vitamins, phytochemicals, nucleosides and cholic acid derivatives, which have all been observed bound to structures in the pdb and are known to stabilize proteins, thereby increasing the chances of crystallisation. Morpheus III was designed using precipitant and buffer mixes from Morpheus I as a robust backbone for testing drug-like compounds as additives.
Gorrec, F. The current approach to initial crystallization screening of proteins is under-sampled. Journal of Applied Crystallography 46: 795-7 (2013).

 

Buy

ASK THE EXPERT

Recommended

Europe & the
rest of the world

Unit 6, Goodwin Business Park
Willie Snaith Road,
Newmarket,
Suffolk, CB8 7SQ, UK

Phone +44 (0)1638 561051
Fax +44 (0)1638 660674
Technical: enquiries@moleculardimensions.com
Sales: orders@moleculardimensions.com

Privacy Policy

USA, Canada, Mexico,
Central & South America

434 West Dussel Drive
Maumee
OH 43537
USA

Phone +1 877 479 4339 / +1 407 886 6901
Fax +1 321 972-8896
Technical: enquiries@moleculardimensions.com
Sales: usorders@moleculardimensions.com

Follow us

FB Like Icon Twitter Icon

LinkedIn Icon

YouTube Icon

Pinterest Icon